Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2025-12-29 @ 9:04 PM
Study NCT ID:
NCT00450203
Status:
UNKNOWN
Last Update Posted:
2016-12-01
First Post:
2007-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D015251', 'term': 'Epirubicin'}, {'id': 'D017024', 'term': 'Chemotherapy, Adjuvant'}, {'id': 'D020360', 'term': 'Neoadjuvant Therapy'}, {'id': 'D000077341', 'term': 'Lapatinib'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D003131', 'term': 'Combined Modality Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D011799', 'term': 'Quinazolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1103}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2007-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-11', 'completionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-11-30', 'studyFirstSubmitDate': '2007-03-20', 'studyFirstSubmitQcDate': '2007-03-20', 'lastUpdatePostDateStruct': {'date': '2016-12-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-03-22', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety', 'timeFrame': 'at the end of phase II and phase III'}, {'measure': 'Efficacy', 'timeFrame': 'end of trial'}, {'measure': 'Overall survival', 'timeFrame': 'end of trial'}], 'secondaryOutcomes': [{'measure': 'Feasibility', 'timeFrame': 'end of trial'}, {'measure': 'Treatment-related morbidity', 'timeFrame': 'end of trial'}, {'measure': 'Response rates to pre-operative treatment', 'timeFrame': 'at phase II review and at end of trial'}, {'measure': 'Surgical resection rates', 'timeFrame': 'end of trial'}, {'measure': 'Disease-free survival', 'timeFrame': 'end of trial'}, {'measure': 'Quality of life', 'timeFrame': 'end of trial'}, {'measure': 'Cost-effectiveness', 'timeFrame': 'end of trial'}, {'measure': 'HER-2 Positivity Rate', 'timeFrame': 'End of trial'}, {'measure': 'Feasibility of centralised HER-2 testing', 'timeFrame': 'After 60 patients tested and then after 110 patients tested and then at end of trial'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['adenocarcinoma of the stomach', 'adenocarcinoma of the gastro oesophageal junction', 'adenocarcinoma of the lower oesophagus'], 'conditions': ['Oesophagogastric Cancer']}, 'referencesModule': {'references': [{'pmid': '23108952', 'type': 'RESULT', 'citation': 'Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013 Mar;24(3):702-9. doi: 10.1093/annonc/mds533. Epub 2012 Oct 28.'}, {'pmid': '31268180', 'type': 'DERIVED', 'citation': 'Allum WH, Smyth EC, Blazeby JM, Grabsch HI, Griffin SM, Rowley S, Cafferty FH, Langley RE, Cunningham D. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. Br J Surg. 2019 Aug;106(9):1204-1215. doi: 10.1002/bjs.11184. Epub 2019 Jul 3.'}, {'pmid': '28163000', 'type': 'DERIVED', 'citation': 'Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.'}], 'seeAlsoLinks': [{'url': 'http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=33', 'label': 'Medical Research Council ST03 Clinical Trial Page'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Lapatinib targets a specific growth receptor, HER-2. Chemotherapy together with bevacizumab or lapatinib, in HER-2 positive tumours, may kill more tumor cells.\n\nPURPOSE: This randomized phase II/III trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works compared with combination chemotherapy alone in treating patients with previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients with HER-2 positive previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study will also assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this patient population.', 'detailedDescription': 'OBJECTIVES:\n\nPrimary\n\n* Assess the safety and efficacy of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride, cisplatin, and capecitabine with or without bevacizumab in patients with previously untreated, resectable gastric, gastroesophageal junction or lower oesophageal cancer.\n* Assess the safety of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride, cisplatin, and capecitabine with or without lapatinib in patients with HER-2 positive previously untreated, resectable gastric, gastroesophageal junction or lower oesophageal cancer.\n\nOUTLINE: This is a multicenter, randomized, open-label, controlled study. Patients are randomized to 1 of 4 treatment arms.\n\n* Arm I and II: Patients receive epirubicin hydrochloride IV and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nPatients undergo surgery 5-6 weeks after completion of chemotherapy. Patients then receive 3 additional courses of chemotherapy beginning 6-10 weeks after surgery.\n\n* Arm II: Patients receive bevacizumab IV over 30-90 minutes, epirubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nPatients undergo surgery 5-8 weeks after completion of chemotherapy. Patients then receive 3 additional courses of chemotherapy and bevacizumab beginning 6-10 weeks after surgery. Patients then receive maintenance therapy comprising bevacizumab IV over 30-90 minutes on day 1. Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\n* Arm IV: Patients receive lapatinib orally once daily, epirubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nPatients undergo surgery 5-8 weeks after completion of chemotherapy. Patients then receive 3 additional courses of chemotherapy and lapatinib beginning 6-10 weeks after surgery. Patients then receive maintenance therapy comprising lapatinib orally once daily on days 1-21. Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nQuality of life is assessed at baseline, during treatment, and during the follow-up period.\n\nAfter completion of study treatment, patients are followed at 9, 18, and 27 weeks after the start of course 4, 1 year post surgery, every 6 months for 2 years, and then annually thereafter.\n\nPROJECTED ACCRUAL: A total of 1063 patients were recruited to the bevacizumab comparison of the study (now closed to recruitment) and 40 patients with HER-2 positive tumours will be recruited into the ST03 feasibility study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "This is a combined eligibility criteria for both bevacizumab comparison and the lapatinib feasibility study. Please note the bevacizumab comparison closed to recruitment on 28th March 2014.\n\nDISEASE CHARACTERISTICS:\n\n* Histologically confirmed gastric or type I, II or III gastroesophageal junction adenocarcinoma or lower oesophageal\n\nGastric and Type III junctional tumours should be Stage Ib (T1 N1, T2a/b N0), II, III or stage IV (T4 N1 or N2) with no evidence of distant metastases (M0)\n\nLower oesophageal and Type I and II junctional tumours should be Stage II to Stage IVa (T1 N1, T2 N1, T3 N0-1, but not T2N0). T4 (N0 or N1) tumours are also eligible providing that they involve only the crura OR invade only the mediastinal pleura. Patients with nodal disease affecting the origin of the left gastric and splenic artery or coeliac axis (staged as M1a) are also eligible.\n\n* Resectable disease\n* Previously untreated disease\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0 or 1\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 9 g/dL (can be post transfusion)\n* WBC ≥ 3,000/mm\\^3\n* Glomerular filtration rate ≥ 60 mL/min\n* Proteinuria ≤ 1 g by 24-hour urine collection\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* ALT and AST ≤ 2.5 times ULN\n* Alkaline phosphatase ≤ 3 times ULN (in the absence of liver metastases)\n* INR ≤ 1.5\n* PTT ≤ 1.5 times ULN\n* FEV\\_1 ≥ 1.5 L\n* Cardiac ejection fraction ≥ 50% by MUGA scan or echocardiogram\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Must be fit enough to receive protocol treatment\n* No other malignancies within the past 5 years except for curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix\n* No prior or concurrent significant medical conditions, including any of the following:\n\n * Cerebrovascular disease (including transient ischemic attack and stroke) within the past year\n * Cardiovascular disease, including the following:\n\n * Myocardial infarction within the past year\n * Uncontrolled hypertension while receiving chronic medication\n * Unstable angina\n * New York Heart Association class II-IV congestive heart failure\n * Serious cardiac arrhythmia requiring medication\n * Major trauma within the past 28 days\n * Serious nonhealing wound, ulcer, or bone fracture\n * Evidence of bleeding diathesis or coagulopathy\n * Recent history of any active gastrointestinal inflammatory condition (e.g., peptic ulcer disease, diverticulitis, or inflammatory bowel disease)\n\n * If patients have a known diagnosis of any of the above, evidence of disease control is required by negative endoscopy within the past 28 days\n* No severe tinnitus\n* No lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication\n* No known peripheral neuropathy ≥ 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible)\n* No known dihydropyrimidine dehydrogenase deficiency\n* No history of interstitial lung disease or radiological evidence of lung fibrosis\n* No known allergy to any of the following:\n\n * Chinese hamster ovary cell proteins\n * Other recombinant human or humanized antibodies\n * Any excipients of bevacizumab formulation or platinum compounds\n * Any other components of the study drugs\n\nDue to an increase in perforations associated with self-expandable metal stents in patients with colorectal cancer receiving bevacizumab, patients with an oesophageal or gastric stent (metal or biodegradable) in situ are ineligible for the study.\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior anthracycline\n* More than 28 days since prior major surgery or open biopsy\n* More than 10 days since prior thrombolytic therapy\n* No concurrent thrombolytic therapy\n* No concurrent dipyridamole\n* No concurrent capecitabine or sorivudine (or sorivudine analogues \\[e.g., brivudine\\])\n* No chronic, daily high-dose acetylsalicylic acid (\\> 325 mg/day) or nonsteroidal anti-inflammatory drugs\n* No chronic corticosteroids (≥ 10 mg/day methylprednisolone equivalent)\n\n * Inhaled steroids allowed\n* No other concurrent cytotoxic agents\n* No other concurrent investigational drugs\n* No concurrent radiotherapy\n* Low molecular weight heparin allowed\n* More than 7 days since prior CYP3A4 inhibitor therapy\n* More than 14 days since prior CYP3A4 inducer therapy\n* More than 6 months since prior amiodarone therapy\n* More than 14 days since prior St John's Wort, modafinil, ginkgo biloba, kava, grape seed, valerian, ginseng, echinacea and evening primrose oil"}, 'identificationModule': {'nctId': 'NCT00450203', 'acronym': 'ST03', 'briefTitle': 'Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Medical Research Council'}, 'officialTitle': 'A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies', 'orgStudyIdInfo': {'id': 'CDR0000536013'}, 'secondaryIdInfos': [{'id': 'MRC-ST03', 'type': 'OTHER', 'domain': 'MRC'}, {'id': 'EU-20710'}, {'id': 'ISRCTN46020948', 'type': 'OTHER', 'domain': 'ISRCTN'}, {'id': '2006-000811-12', 'type': 'EUDRACT_NUMBER'}, {'id': '00316/0221/001', 'type': 'OTHER', 'domain': 'CTA'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ECX + Bevacizumab', 'description': 'ECX + Bevacizumab', 'interventionNames': ['Biological: bevacizumab', 'Drug: capecitabine', 'Drug: cisplatin', 'Drug: Epirubicin', 'Procedure: adjuvant therapy', 'Procedure: conventional surgery', 'Procedure: neoadjuvant therapy']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Epirubicin, Cisplatin and Capecitabine', 'description': 'ECX chemotherapy', 'interventionNames': ['Drug: capecitabine', 'Drug: cisplatin', 'Drug: Epirubicin', 'Procedure: adjuvant therapy', 'Procedure: conventional surgery', 'Procedure: neoadjuvant therapy']}, {'type': 'EXPERIMENTAL', 'label': 'ECX + Lapatinib', 'description': 'ECX + Lapatinib', 'interventionNames': ['Drug: capecitabine', 'Drug: cisplatin', 'Drug: Epirubicin', 'Procedure: adjuvant therapy', 'Procedure: conventional surgery', 'Procedure: neoadjuvant therapy', 'Drug: Lapatinib']}], 'interventions': [{'name': 'bevacizumab', 'type': 'BIOLOGICAL', 'description': '7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.', 'armGroupLabels': ['ECX + Bevacizumab']}, {'name': 'capecitabine', 'type': 'DRUG', 'description': 'dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'cisplatin', 'type': 'DRUG', 'description': '60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'Epirubicin', 'type': 'DRUG', 'description': '50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'adjuvant therapy', 'type': 'PROCEDURE', 'description': '3 cycles of ECX chemotherapy post operatively', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'conventional surgery', 'type': 'PROCEDURE', 'description': 'Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'neoadjuvant therapy', 'type': 'PROCEDURE', 'description': '3 cycles of pre-operative ECX chemotherapy.', 'armGroupLabels': ['ECX + Bevacizumab', 'ECX + Lapatinib', 'Epirubicin, Cisplatin and Capecitabine']}, {'name': 'Lapatinib', 'type': 'DRUG', 'otherNames': ['Tyverb'], 'description': '1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.', 'armGroupLabels': ['ECX + Lapatinib']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'BH7 7DW', 'city': 'Bournemouth', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tom Geldart', 'role': 'CONTACT', 'phone': '44-1202-726-088'}], 'facility': 'Royal Bournemouth Hospital', 'geoPoint': {'lat': 50.72048, 'lon': -1.8795}}, {'zip': 'BD9 6RJ', 'city': 'Bradford', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Bradford Royal Infirmary', 'geoPoint': {'lat': 53.79391, 'lon': -1.75206}}, {'zip': 'BS2 8ED', 'city': 'Bristol', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Stephen J. Falk, MD', 'role': 'CONTACT', 'email': 'stephen.falk@ubht.nhs.uk', 'phone': '44-117-928-3074'}], 'facility': 'Bristol Haematology and Oncology Centre', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'CB2 2QQ', 'city': 'Cambridge', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': "Addenbrooke's Hospital", 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'CA2 7HY', 'city': 'Carlisle', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Cumberland Infirmary', 'geoPoint': {'lat': 54.8951, 'lon': -2.9382}}, {'zip': 'DN2 5LT', 'city': 'Doncaster', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Jonathan Wadsley', 'role': 'CONTACT', 'phone': '44-1302-366-666'}], 'facility': 'Doncaster Royal Infirmary', 'geoPoint': {'lat': 53.52285, 'lon': -1.13116}}, {'zip': 'GU2 7XX', 'city': 'Guildford', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Gary W. Middleton', 'role': 'CONTACT', 'email': 'gmiddleton@royalsurrey.nhs.uk', 'phone': '44-1483-570-122'}], 'facility': "St. Luke's Cancer Centre at Royal Surrey County Hospital", 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'zip': 'HD3 3EA', 'city': 'Huddersfield, West Yorks', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Jo Dent', 'role': 'CONTACT', 'phone': '44-1484-342-000'}], 'facility': 'Huddersfield Royal Infirmary', 'geoPoint': {'lat': 53.64904, 'lon': -1.78416}}, {'zip': 'LS9 7TF', 'city': 'Leeds', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Matthew T. Seymour, MA, MD, FRCP', 'role': 'CONTACT', 'phone': '44-113-206-6400'}], 'facility': "Leeds Cancer Centre at St. James's University Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'LN2 5QY', 'city': 'Lincoln', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Lincoln County Hospital', 'geoPoint': {'lat': 53.22683, 'lon': -0.53792}}, {'zip': 'L9 7AL', 'city': 'Liverpool', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'David Smith, MD', 'role': 'CONTACT', 'phone': '44-151-525-5980'}], 'facility': 'Aintree University Hospital', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'EC1A 7BE', 'city': 'London', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Sarah Slater, MD', 'role': 'CONTACT', 'phone': '44-20-7601-8391'}], 'facility': "Saint Bartholomew's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW17 0QT', 'city': 'London', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': "St. George's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'W2 1NY', 'city': 'London', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': "St. Mary's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'ME16 9QQ', 'city': 'Maidstone', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Justin Waters, MD', 'role': 'CONTACT', 'phone': '44-1622-729-000'}], 'facility': 'Mid Kent Oncology Centre at Maidstone Hospital', 'geoPoint': {'lat': 51.26667, 'lon': 0.51667}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Was Mansoor, MD', 'role': 'CONTACT', 'phone': '44-845-226-3000'}], 'facility': 'Christie Hospital', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'CH63 4JY', 'city': 'Merseyside', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'David Smith, MD', 'role': 'CONTACT', 'email': 'david.smith@ccotrust.nhs.uk', 'phone': '44-151-334-1155'}], 'facility': 'Clatterbridge Centre for Oncology'}, {'zip': 'NE4 6BE', 'city': 'Newcastle upon Tyne', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Fareeda Coxon, MD', 'role': 'CONTACT', 'email': 'fareeda.coxon@nuth.nhs.uk', 'phone': '44-191-256-3551'}], 'facility': 'Northern Centre for Cancer Treatment at Newcastle General Hospital', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'PL6 8DH', 'city': 'Plymouth', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Derriford Hospital', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'BH15 2JB', 'city': 'Poole Dorset', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Dorset Cancer Centre'}, {'zip': 'RG1 5AN', 'city': 'Reading', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Joss Adams, MD', 'role': 'CONTACT', 'phone': '44-118-322-7878'}], 'facility': 'Berkshire Cancer Centre at Royal Berkshire Hospital', 'geoPoint': {'lat': 51.45625, 'lon': -0.97113}}, {'zip': '0L12 0NB', 'city': 'Rochdale', 'state': 'England', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'Rochdale Infirmary', 'geoPoint': {'lat': 53.61766, 'lon': -2.1552}}, {'zip': 'SP2 8BJ', 'city': 'Salisbury', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tim J. Iveson, MD', 'role': 'CONTACT', 'phone': '44-1722-336-262 ext. 4688'}], 'facility': 'Salisbury District Hospital', 'geoPoint': {'lat': 51.06931, 'lon': -1.79569}}, {'zip': 'SL2 4HL', 'city': 'Slough, Berkshire', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Marcia Hall, MD', 'role': 'CONTACT', 'email': 'marcia.hall@nhs.net.uk', 'phone': '44-1753-634-364'}], 'facility': 'Wexham Park Hospital', 'geoPoint': {'lat': 51.50949, 'lon': -0.59541}}, {'zip': 'SO16 6YD', 'city': 'Southampton', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tim J. Iveson, MD', 'role': 'CONTACT', 'email': 't.iveson@soton.ac.uk', 'phone': '44-23-8079-6802'}], 'facility': 'Southampton General Hospital', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'David Cunningham, MD', 'role': 'CONTACT', 'email': 'david.cunningham@rmh.nhs.uk', 'phone': '44-20-8661-3279'}], 'facility': 'Royal Marsden - Surrey', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'AB25 2ZN', 'city': 'Aberdeen', 'state': 'Scotland', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Russell Petty, MD', 'role': 'CONTACT', 'phone': '44-84-5456-6000'}], 'facility': 'Aberdeen Royal Infirmary', 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'zip': 'CF14 2TL', 'city': 'Cardiff', 'state': 'Wales', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tom Crosby, MD', 'role': 'CONTACT', 'phone': '44-29-2031-6292'}], 'facility': 'Velindre Cancer Center at Velindre Hospital', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'city': 'Basingstoke', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Charlotte Rees', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Basingstoke and North Hampshire Hospital', 'geoPoint': {'lat': 51.26249, 'lon': -1.08708}}, {'city': 'Birmingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Jo Dent', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Birmingham Heartlands Hospital', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'city': 'Cottingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Mohan Hingorani', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Castle Hill Hospital', 'geoPoint': {'lat': 52.50243, 'lon': -0.7554}}, {'city': 'Coventry', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Sharmila Sothi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Hospitals Coventry and Warwickshire', 'geoPoint': {'lat': 52.40656, 'lon': -1.51217}}, {'city': 'Glasgow', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Janet Graham', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Beatson West of Scotland Cancer Centre', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'city': 'Leeds', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Matt Seymour', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'St James Hospital', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'Leicester', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Anne Thomas', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Leicester Royal Infirmary', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'city': 'Norwich', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tom Roques', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Norfolk and Norwich University Hospital', 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}, {'city': 'Oxford', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Kinnari Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Churchill Hospital', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}, {'city': 'Romford', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Sherif Raouf', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Queens Hospital', 'geoPoint': {'lat': 51.57515, 'lon': 0.18582}}, {'city': 'Sheffield', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Suzanne Darby', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Weston Park', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'city': 'Swindon', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Claire Blesing', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Great Western Hospital', 'geoPoint': {'lat': 51.55797, 'lon': -1.78116}}, {'city': 'Taunton', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Emma Cattell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Musgrove Park Hospital', 'geoPoint': {'lat': 51.01494, 'lon': -3.10293}}], 'centralContacts': [{'name': 'Nicholas Kleovoulou', 'role': 'CONTACT', 'email': 'n.kleovoulou@ucl.ac.uk', 'phone': '0207 670 4801'}], 'overallOfficials': [{'name': 'David Cunningham, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Royal Marsden NHS Foundation Trust'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Professor David Cunningham', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Cancer Research UK', 'class': 'OTHER'}, {'name': 'Roche Pharma AG', 'class': 'INDUSTRY'}, {'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'ST03 Chief Investigator, Professor David Cunningham', 'investigatorFullName': 'Professor David Cunningham', 'investigatorAffiliation': 'Medical Research Council'}}}}